207 related articles for article (PubMed ID: 35989655)
41. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
42. The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease.
Zeng Y; Ni J; Yu F; Zhou Y; Zhao Y; Li S; Guo T; Chu L; Yang X; Chu X; Cai X; Zhu Z
Radiat Oncol; 2020 Aug; 15(1):207. PubMed ID: 32854745
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
Breadner D; Blanchette P; Shanmuganathan S; Boldt RG; Raphael J
Lung Cancer; 2020 Jun; 144():57-63. PubMed ID: 32371261
[TBL] [Abstract][Full Text] [Related]
44. Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
Chen Y; Jiang L; Gao B; Cheng ZY; Jin J; Yang KH
Breast Cancer Res Treat; 2016 Jun; 157(3):517-25. PubMed ID: 27246814
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Liu J; Guo J; Sun X; Liu Y; Gao C
Front Oncol; 2021; 11():799721. PubMed ID: 35096600
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
Zhang C; Ma N; Zhang Q; Zheng K; Sun C; Tang X; Li X; Zhao J
J Thorac Dis; 2021 Oct; 13(10):5899-5910. PubMed ID: 34795938
[TBL] [Abstract][Full Text] [Related]
48. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
49. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC.
Farooqi A; Ludmir EB; Mitchell KG; Antonoff MB; Tang C; Lee P; Chang J; Elamin Y; Gomez DR; Gandhi SJ
Radiother Oncol; 2021 Oct; 163():114-118. PubMed ID: 34419505
[TBL] [Abstract][Full Text] [Related]
50. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.
Chakraborty R; Siddiqi R; Willson G; Gupta S; Asghar N; Husnain M; Aljama MA; Behera TR; Anwer F; Perrot A; Riaz IB
Cancer; 2022 Jun; 128(12):2288-2297. PubMed ID: 35377484
[TBL] [Abstract][Full Text] [Related]
51. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
52. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
53. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
55. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer.
Luo HQ; Han L; Jiang Y
Asian Pac J Cancer Prev; 2014; 15(13):5343-8. PubMed ID: 25040999
[TBL] [Abstract][Full Text] [Related]
56. Radiotherapy for diffuse brainstem glioma in children and young adults.
Hu X; Fang Y; Hui X; Jv Y; You C
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD010439. PubMed ID: 27378212
[TBL] [Abstract][Full Text] [Related]
57. Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Manneh R; Lema M; Carril-Ajuria L; Ibatá L; Martínez S; Castellano D; de Velasco G
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327380
[TBL] [Abstract][Full Text] [Related]
58. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
[TBL] [Abstract][Full Text] [Related]
59. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
